Ewing's sarcoma with an uncommon clinical course: A case report

Niimi,Rui; Matsumine,Akihiko; Nakamura,Tomiki; Morimoto,Ryo; Murata,Tetsuya; Suzuki,Takashi; Nakashima,Yasuaki; Nojima,Takayuki; Uchida,Atsumasa; Sudo,Akihiro

doi:10.3892/ol.2013.1320

Ewing's sarcoma with an uncommon clinical course: A case report

Authors:
- Rui Niimi
- Akihiko Matsumine
- Tomiki Nakamura
- Ryo Morimoto
- Tetsuya Murata
- Takashi Suzuki
- Yasuaki Nakashima
- Takayuki Nojima
- Atsumasa Uchida
- Akihiro Sudo
View Affiliations

Affiliations: Department of Orthopaedic Surgery, Mie University Graduate School of Medicine, Tsu City, Mie 514-8507, Japan, Department of Pathology JA Suzuka General Hospital, Suzuka, Mie 513-8630, Japan, School of Pharmacy, Nihon University, Chiba 274-8555, Japan, Laboratory of Anatomic Pathology, Kyoto University Hospital, Sakyo-ku, Kyoto 606-8507, Japan, Department of Pathology and Laboratory Medicine, Kanazawa Medical University, Kahoku-gun, Ishikawa 920-0293, Japan
Published online on: April 26, 2013 https://doi.org/10.3892/ol.2013.1320
Pages: 9-12

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Here, a case of Ewing's sarcoma family of tumors (ESFT) of the femur with an unusual clinical course is reported. At 20 years of age, the patient had undergone curettage of a bone tumor of the right femur which was diagnosed as ESFT. One cycle of chemotherapy with vincristine and cyclophosphamide and radiotherapy for a total dose of 40 Gy was administered. The patient did not develop any recurrence or metastases for the following 18 years, in spite of the inadequacy of the initial treatment. At 38 years of age, he was referred to our institution with right thigh pain that had persisted for several months. Radiographs and magnetic resonance imaging findings showed a mass lesion in his proximal femur extending to the soft tissue. An open biopsy was performed and the lesion was diagnosed as recurrence of ESFT, although a molecular biological investigation did not reveal any expression of the characteristic fusion genes that have previously been reported. The patient received standard multimodal therapy employing standard combination chemotherapy for ESFT and wide surgical excision. The patient has been disease-free for 9 years since the treatment. This patient may have a rare subtype of ESFT with an unknown chromosomal translocation and relatively non-aggressive biological behavior.

View Figures

View References

1.	Delattre O, Zucman J, Plougastel B, et al: Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature. 359:162–165. 1992. View Article : Google Scholar : PubMed/NCBI
2.	Arvand A and Denny CT: Biology of EWS/ETS fusions in Ewing’s family tumors. Oncogene. 20:5747–5754. 2001.
3.	Delattre O, Zucman J, Melot T, et al: The Ewing family of tumors - a subgroup of small-round-cell tumors defined by specific chimeric transcripts. N Engl J Med. 331:294–299. 1994. View Article : Google Scholar : PubMed/NCBI
4.	Sorensen PH, Lessnick SL, Lopez-Terrada D, Liu XF, Triche TJ and Denny CT: A second Ewing’s sarcoma translocation, t(21;22), fuses the EWS gene to another ETS-family transcription factor, ERG. Nat Genet. 6:146–151. 1994.
5.	Zucman J, Melot T, Desmaze C, et al: Combinatorial generation of variable fusion proteins in the Ewing family of tumours. EMBO J. 12:4481–4487. 1993.PubMed/NCBI
6.	Peter M, Couturier J, Pacquement H, et al: A new member of the ETS family fused to EWS in Ewing tumors. Oncogene. 14:1159–1164. 1997. View Article : Google Scholar : PubMed/NCBI
7.	Kaneko Y, Yoshida K, Handa M, et al: Fusion of an ETS-family gene, E1AF, to EWS by t(17;22)(q12;q12) chromosome trans-location in an undifferentiated sarcoma of infancy. Genes Chromosomes Cancer. 15:115–121. 1996. View Article : Google Scholar : PubMed/NCBI
8.	Urano F, Umezawa A, Hong W, Kikuchi H and Hata J: A novel chimera gene between EWS and E1A-F, encoding the adenovirus E1A enhancer- binding protein, in extraosseous Ewing’s sarcoma. Biochem Biophys Res Commun. 219:608–612. 1996.PubMed/NCBI
9.	Jeon IS, Davis JN, Braun BS, et al: A variant Ewing’s sarcoma translocation (7;22) fuses the EWS gene to the ETS gene ETV1. Oncogene. 10:1229–1234. 1995.
10.	Smith MA, Seibel NL, Altekruse SF, et al: Outcomes for children and adolescents with cancer: challenges for the twenty-first century. J Clin Oncol. 28:2625–2634. 2010. View Article : Google Scholar : PubMed/NCBI
11.	Bacci G, Ferrari S, Longhi A, et al: Therapy and survival after recurrence of Ewing’s tumours: the Rizzoli experience in 195 patients treated with ajuvant and neoajuvant chemotherapy from 1979 to 1997. Ann Oncol. 14:1654–1659. 2003.
12.	Paulussen M, Bielack S, Jürgens H and Casali PG; ESMO Guidelines Working Group: Ewing’s sarcoma of the bone: ESMO clinical recommendations for diagnosis,treatment and follow-up. Ann Oncol. 20:140–142. 2009.
13.	Rosito P, Mancini AF, Rondelli R, et al: Italian Cooperative Study for the treatment of children and young adults with localized Ewing sarcoma of bone: a preliminary report of 6 years of experience. Cancer. 86:421–428. 1999.PubMed/NCBI
14.	McTiernan AM, Cassoni AM, Driver D, et al: Improving Outcomes After Relapse in Ewing’s Sarcoma: Analysis of 114 Patients From a Single Institution. Sarcoma. 2006:835482006.PubMed/NCBI
15.	Grier HE, Krailo MD, Tarbell NJ, et al: Addition of ifosfamide and etoposide to standard chemotherapy for Ewing’s sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med. 348:694–701. 2003.
16.	Indelicato DJ, Keole SR, Shahlaee AH, et al: Long-term clinical and functional outcomes after treatment for localized Ewing’s tumor of the lower extremity. Int J Radiat Oncol Biol Phys. 70:501–509. 2008.PubMed/NCBI
17.	Rodríguez-Galindo C, Liu T, Krasin MJ, Wu J, et al: Analysis of prognostic factors in ewing sarcoma family of tumors: review of St. Jude Children’s Research Hospital studies. Cancer. 110:375–384. 2007.
18.	Bacci G, Forni C, Longhi A, et al: Long-term outcome for patients with non-metastatic Ewing’s sarcoma treated with adjuvant and neoadjuvant chemotherapies. 402 patients treated at Rizzoli between 1972 and 1992. Eur J Cancer. 40:73–83. 2004.
19.	Donati D, Yin J, Di Bella C, et al: Local and distant control in non-metastatic pelvic Ewing’s sarcoma patients. J Surg Oncol. 96:19–25. 2007.PubMed/NCBI
20.	Gasparini M, Lombardi F, Ballerini E, et al: Long-term outcome of patients with monostotic Ewing’s sarcoma treated with combined modality. Med Pediatr Oncol. 23:406–412. 1994.PubMed/NCBI
21.	McLean TW, Hertel C, Young ML, et al: Late events in pediatric patients with Ewing sarcoma/primitive neuroectodermal tumor of bone: the Dana-Farber Cancer Institute/Children’s Hospital experience. J Pediatr Hematol Oncol. 2:486–493. 1999.PubMed/NCBI
22.	Lin PP, Jaffe N, Herzog CE, et al: Chemotherapy response is an important predictor of local recurrence in Ewing sarcoma. Cancer. 109:603–611. 2007. View Article : Google Scholar : PubMed/NCBI